Guggenheim Reiterates Buy Rating for Verve Therapeutics (NASDAQ:VERV)

Verve Therapeutics (NASDAQ:VERV)‘s stock had its “buy” rating reissued by investment analysts at Guggenheim in a research report issued on Tuesday,Benzinga reports.

A number of other analysts have also recently commented on VERV. William Blair reiterated an “outperform” rating on shares of Verve Therapeutics in a research note on Friday, February 21st. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of Verve Therapeutics in a research note on Tuesday. Finally, Royal Bank of Canada dropped their price objective on Verve Therapeutics from $17.00 to $15.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 4th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $25.50.

Verve Therapeutics Stock Performance

NASDAQ:VERV opened at $5.40 on Tuesday. Verve Therapeutics has a 52-week low of $4.31 and a 52-week high of $13.63. The company has a market cap of $479.50 million, a P/E ratio of -2.20 and a beta of 1.77. The stock’s 50-day simple moving average is $6.97 and its 200 day simple moving average is $6.09.

Verve Therapeutics (NASDAQ:VERV) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.58) earnings per share for the quarter, topping the consensus estimate of ($0.72) by $0.14. The firm had revenue of $13.08 million for the quarter, compared to analyst estimates of $3.94 million. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. As a group, equities analysts predict that Verve Therapeutics will post -2.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Verve Therapeutics

Institutional investors have recently made changes to their positions in the company. GAMMA Investing LLC lifted its holdings in Verve Therapeutics by 189.7% during the 4th quarter. GAMMA Investing LLC now owns 6,054 shares of the company’s stock worth $34,000 after purchasing an additional 3,964 shares during the last quarter. IFP Advisors Inc lifted its holdings in shares of Verve Therapeutics by 823,700.0% during the fourth quarter. IFP Advisors Inc now owns 8,238 shares of the company’s stock worth $47,000 after buying an additional 8,237 shares in the last quarter. BNP Paribas Financial Markets bought a new stake in shares of Verve Therapeutics in the fourth quarter valued at about $50,000. Erste Asset Management GmbH acquired a new position in shares of Verve Therapeutics in the third quarter valued at about $56,000. Finally, Impact Partnership Wealth LLC bought a new position in Verve Therapeutics during the fourth quarter worth about $70,000. Institutional investors own 97.11% of the company’s stock.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.